anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
For the NMES new paradigm, A portable electrical stimulator will be used to produce simultaneous stimulation to both the quadriceps and calf muscles. The stimulator delivers a biphasic, asymmetrical square wave at a pulse width of 250 μs and duty cycle 5:10 sec with 2 Hz frequencies of stimulation. To disperse current intensity and enhance the comfort of the stimulation, large rectangular electrodes (80 × 100 mm) will be positioned at the best motor points of the quadriceps and calf muscles. The electrodes will be secured by tight short and sock at the respective positions. The stimulation intensity will be set to just visible muscle contractions. Stimuli will be applied twice a day for 3 h (with a 2 h rest between treatments), 5 days a week for 8 weeks.
Age-related hearing loss (ARHL) is an auditory disease characterized by gradual loss of high-frequency hearing sensitivity. Excessive reactive oxygen species trigger NLRP3-inflammasome activation that may be crucial for ARHL pathogenesis. The antioxidant factor Sestrin2 (SESN2) has been reported to be involved in the remission of oxidative stress and ARHL. However, the mechanism by which SESN2 protects auditory cells in the aging mouse cochlea remains unknown. Here, we observed that ectopic overexpression of SESN2 delayed ARHL, whereas SESN2 knockdown accelerated it. Importantly, we elucidated that SESN2 exerts a hearing-protective effect by inhibiting the production of NLRP3 by acting as a mitophagy agonist. Our study proposes a new theoretical basis for SESN2 prevention of ARHL and provides a novel therapeutic strategy for maintaining SESN2 activity in the aging cochlea.
MAN-Group were treated with cervical spine manipulation with SAT. Patients received a total of 3 sessions of treatment over a month (days 1, 15 and 30 after the beginning of the study).
PURPOSE:To obtain the title composition with adequately high absorbability by adding yeast to the seeds or embryo buds of a plant followed by fermentation and then drying into fine powder and by mixing said fine powder with wheat embryo bud oil etc.. CONSTITUTION:(A) The seeds or embryo buds of a plant are roasted and then steamed; followed by addition of yeast to effect fermentation followed by drying into fine powder. Thence, 100 pts.wt. of the product A is mixed with (B) 2 - 50 pts.wt. of a mixture of wheat embryo bud oil, ground sesame and the fine powder of tea leaves. The component B may further be incorporated with at least one kind of fine powder selected from such powder of tempeh, acerola, rose hip and rosemary. The present composition is rich in SOD-like components, thereby adequately having SOD effects and being extremely useful as e.g. a health food.
BACKGROUND: An estimated 3.5 million people in the UK live with a rare disease however due to the rarity of each individual condition this is not currently reflected in mainstream medical education. As a result, common features of living with a rare condition include diagnostic delay, poor coordination of health and social care and lack of access to specialist care and treatment. This is well documented in reports published by patient advocacy groups collating the patient experience and has been highlighted by the Department of Health and Social Care in its UK Rare Diseases Framework. One of the four priority areas outlined in this policy published in 2021 is 'increasing awareness amongst healthcare professionals'. Medics4RareDiseases (M4RD), a charity based in the UK, has proposed a disease-agnostic approach to educating doctors about rare disease, focusing on the common challenges experienced across this heterogeneous collection of conditions, rather than on the minutiae of each of the > 7000 rare conditions. A literature search using MEDLINE, PubMed Central and Bookshelf confirmed a lack of broad rare disease teaching in medical literature; none of the 10 final resources identified focused on the topic as a whole.
RESULTS: To address this, M4RD created the course 'Rare Disease 101'. It is accessed online using a learning management system that is free, contains interactive lessons, hosts a discussion board and is easily updated. In the 29 months since going live, 942 individuals have registered with 204 having completed the course; early feedback from 33 respondents was unanimously positive (all participants rated at least good (76%: excellent)) demonstrating that both clinicians and patients can benefit from broad rare disease education. The course is freely available to all at https://learn.m4rd.org/ .
CONCLUSIONS: Disease-agnostic training about rare disease as a large patient population, focusing on its unique profile of unmet needs, is required. Rare Disease 101 provides a pragmatic approach to an educational challenge that leads to poor patient outcomes. Early results suggest that the educational programme is well-received but further evaluation and assessment is needed.
Subjects will receive 30mg of Placebo for blinded period 1 (first 4 week treatment period) and 60mg of Placebo for blinded period 2 (additional 4 weeks treatment period). After this, subjects will be unblinded and receive routine clinical care for follow up phase (up to 52 weeks).
Digoxin is one of the cardiac (or digitalis) glycosides, a closely related group of drugs having in common specific effects on the myocardium. These drugs are found in a number of plants. Digoxin is extracted from the leaves of Digitalis lanata. The term “digitalis” is used to designate the whole group of glycosides. The glycosides are composed of two portions: a sugar and a cardenolide (hence “glycosides”).

Digoxin has the chemical name: 3β-[(O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-O-2,6-dideoxy-β-D-ribo-hexopy­ranosyl-(1→4)-2,6-dideoxy-β-D-ribo-hexopyranosyl)oxy]-12β,14-dihydroxy-5β-card-20(22)-enolide, and the following structural formula:

C41H64O14 MW 780.94

Digoxin exists as odorless white crystals that melt with decomposition above 230°C. The drug is practically insoluble in water and in ether; slightly soluble in diluted (50%) alcohol and in chloroform; and freely soluble in pyridine.

Digoxin Injection is a sterile solution for slow intravenous or deep intramuscular injection. Each mL contains digoxin 250 mcg (0.25 mg), alcohol 0.1 mL, propylene glycol 0.4 mL, dibasic sodium phosphate, anhydrous 3 mg and citric acid, anhydrous 0.8 mg in Water for Injection. pH 6.7-7.3; citric acid and/or sodium phosphate added, if necessary, for pH adjustment. Dilution is not required.
This invention relates to the technical field of TCM, specifically discloses a traditional Chinese medicine composition for treating perianal diseases. The traditional Chinese medicine composition is prepared from, by weight, 20 to 50 parts of Sophora flavescens, 5-20 parts of Coptis chinensis, 15-40 parts of baical skullcap root, 20-35 parts of raw Radix Sanguisorbae, 15-45 parts of Portulaca oleracea, 10-30 parts of Radix stemonae, 25-35 parts of Sophora japonica, 10-30 parts of dandelion, 15-25 parts of Fructus kochiae, 10-30 parts of Fructus cnidii and 20-35 parts of Rheum officinale. This invention provides a traditional Chinese medicine composition for treating perianal diseases. This medicine has the functions of detoxifying and detoxifying and eliminating itching and dampness by means of rational combination of the above-mentioned raw materials. Through fumigation and washing acting on the affected area, it can effectively treat the itching symptoms caused by perianal diseases such as hemorrhoids, anal fistula, anal fissure and perianal eczema, anal acne. It is clinically proved that this invention has a significant effect in treating perianal diseases among traditional Chinese medicine composition.
The present invention relates to a wet tissue composition comprising lauryl pyridinium chloride, organic acid and polyhydric alcohol or a mixture thereof, and wet tissue containing the same. It is found that there is a bacterium called Burkholderia spp. resistant to a wet tissue composition disclosed in a Korean registered patent No. 1798978 filed by the present inventors and unpleasant smell and discoloration take place in the wet tissue containing the wet tissue composition. In order to solve such problems, when organic acid and polyhydric alcohol or a mixture thereof not described in the above registered patent are added along with lauryl pyridinium chloride, it is confirmed that the inventive composition has an anti-bacterial effect on Burkholderia spp. resistant to the prior composition and excellent diffusivity in wet tissue and the unpleasant smell and discoloration do not appear. Therefore, the wet tissue composition comprising lauryl pyridinium chloride, an organic acid and polyhydric alcohol or a mixture thereof according to the present invention is expected to replace a wet tissue composition of the registered patent filed by the present inventors (Korean registered patent No. 1798978) as well as a conventional antiseptic composition comprising cetylpyridinium chloride.
The present disclosure is related to systems and methods for generating a radiation treatment plan for a treatment volume of a subject. The method includes retrieving a planning image of the treatment volume. The planning image may include a plurality of first voxels. The method also includes retrieving a treatment image that represents at least part of the treatment volume. The treatment image may include a plurality of second voxels. For at least one of the plurality of second voxels, the method further includes determining at least one reference voxel among the plurality of first voxels in the planning image and determining a dose value corresponding to the at least one second voxel. The method still further includes generating a radiation treatment plan based at least part on the dose value corresponding to the at least one second voxel.
OBJECTIVE: To identify and synthesize patient-related barriers to and enablers of the implementation of high-value physiotherapy (HVP) for chronic pain. Furthermore, to review what patient-related interventions have been used to facilitate the implementation of HVP for chronic pain, as well as their efficacy.
METHODS: We systematically searched the APA PsycInfo, Embase, CINAHL, Medline, Scopus, and PEDro databases for peer-reviewed studies (published in English) of adults with chronic pain. We used the Theoretical Domains Framework of behavior change to synthesize identified themes relating to barriers and enablers. Outcomes from studies reporting on interventions were also qualitatively synthesized.
RESULTS: Fourteen studies reported on barriers and enablers, 8 of which related to exercise adherence. Themes common to barriers and enablers included perceived efficacy of treatment, interrelationship with the physiotherapist, exercise burden, and the patient's understanding of exercise benefits. Other barriers included fear of movement, fragmented care, and cost. Ten studies explored interventions, 9 of which aimed to improve exercise adherence. Of these, evidence from 4 randomized controlled trials of technology-based interventions demonstrated improved exercise adherence among intervention groups compared with controls.
CONCLUSION: Patients with chronic pain experience barriers to HVP, including their beliefs, the nature of their interaction with their physiotherapist, perceived treatment efficacy, and cost. Enablers include rapport with their physiotherapist, achievable exercises, and seamless cost-effective care. Technology-based interventions have demonstrated effectiveness at increasing exercise adherence. Our findings suggest that interventions seeking to enhance implementation of HVP need to consider the multifactorial barriers experienced by patients with chronic pain.
STUDY REGISTRATION: Open Science Framework (https://doi.org/10.17605/OSF.IO/AYGZV).
Carboplatin AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles. Pemetrexed 500 mg/m2 by vein on day 1 of each 21 day cycle.
Patient will receive 70Gy in 2Gy per fraction regardless of hypoxia status. Concurrent chemotherapy will be given as per guidelines. After completion of chemotherapy and radiation therapy, a 4 month (+/- 4 weeks) posttreatment standard FDG PET/CT scan will be performed and if there is persistent disease, standard neck dissection will be performed. Further standard of care will be given pending pathologic findings.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare form of pulmonary hypertension characterized by the presence of organized thrombi that obstruct pulmonary arteries, ultimately leading to right heart failure and death. Among others, impaired angiogenesis and inflammatory thrombosis have been shown to contribute to the progression of CTEPH. In this review, we summarize the 2-faced nature of angiogenesis in both thrombus formation and resolution in the context of CTEPH and highlight the dual role of angiogenesis and neovascularization in resolving venous thrombi. Furthermore, we discuss relevant in vitro and in vivo models that support the benefits or drawbacks of angiogenesis in CTEPH progression. We discuss the key pathways involved in modulating angiogenesis, particularly the underexplored role of TGFβ (transforming growth factor-beta) signaling in driving fibrosis as an integral element of CTEPH pathogenesis. We finally explore innovative treatment strategies that target angiogenic pathways. These strategies have the potential to pioneer preventive, inventive, or alternative therapeutic options for patients with CTEPH who may not qualify for surgical interventions. Moreover, they could be used synergistically with established treatments such as pulmonary endarterectomy or balloon pulmonary angioplasty. In summary, this review emphasizes the crucial role of angiogenesis in the development of in fibrothrombotic tissue, a major pathological characteristic of CTEPH.
This invention discloses Bacillus anthracis gamma-phase lyase epitope, its lyase mutant and application. This invention provides the epitope of Bacillus anthracis gamma-phase lyase PlyG, and mutant lyase MPlyG. The epitope is 164th-172nd amino acid residues of lyase PlyG, and is shown in SEQ ID No.4. Mutant lyase MPlyG is derived from lyase PlyG by deleting one or more of 164th-172nd amino acid residues. Animal experiments show that compared with PlyG, MPlyG has lower antigenicity, lower immunogenicity, and similar lyase activity. Therefore, MPlyG can be used to prevent and treat charbon and manufacture corresponding drugs.
The present invention relates to a pharmaceutical composition for preventing or treating bone diseases comprising a fusion peptide in which a bone tissue-selective peptide bound to parathyroid hormone (PTH) or a fragment thereof. More particularly, the present invention relates to a pharmaceutical composition and biomaterial for preventing or treating bone diseases comprising a fusion peptide in which a bone tissue-selective peptide represented by an amino acid sequence of SEQ ID NO. 3 bound to parathyroid hormone (PTH) or a fragment thereof represented by an amino acid sequence of SEQ ID NO. 4 or 5. The fusion peptide can improve effects of PTH by selectively binding to bone tissue and can reduce administration frequency by increasing the half-life. The fusion peptide can be used as a subcutaneous or intravenous injection-type pharmaceutical composition for treating osteoporosis and fracture, and can be used in combination with a medical device for tissue recovery to increase formation of bone tissue. In addition, when the fusion peptide is bound to the surface of dental and orthopedic medical devices, transplantation stability of the medical device can be improved through improved osseointegration between the medical device and new bone.
This study aims to determine if active external rotation two years postoperatively varies based on whether an inlay or onlay humeral component is used in reverse shoulder arthroplasty (RTSA). The study also aims to determine whether active forward elevation, abduction, scapular notching, and functional outcomes two years postoperatively vary based on whether an inlay or onlay humeral component is used in reverse shoulder arthroplasty. Patients undergoing primary RTSA by Dr. J. Michael Wiater, Dr. Brett Wiater, or Dr. Alexander Martusiewicz at Beaumont Health will be screened for eligibility. Following informed consent, participants will be randomised (1:1) to one of the following groups: 1) RTSA with inlay humeral component (Tornier Perform Stem Reverse+) or 2) RTSA with onlay humeral component (Tornier Ascend Flex stem). At baseline, participants will complete study questionnaires, receive a range-of-motion (ROM) exam, and standard of care x-rays and computed tomography (CT) scans. These evaluations will be repeated at 3 months, 12 months and 24 months.
In recent years, clinical studies have shown positive results of the application of Mesenchymal Stromal Cells (MSCs) in severe cases of COVID-19. However, the mechanisms of immunomodulation of IFN-γ licensed MSCs in SARS-CoV-2 infection are only partially understood. In this study, we first tested the effect of IFN-γ licensing in the MSC immunomodulatory profile. Then, we established an in vitro model of inflammation by exposing Calu-3 lung cells to SARS-CoV-2 nucleocapsid and spike (NS) antigens, and determined the toxicity of SARS-CoV-2 NS antigen and/or IFN-γ stimulation to Calu-3. The conditioned medium (iCM) generated by Calu-3 cells exposed to IFN-γ and SARS-CoV-2 NS antigens was used to stimulate T-cells, which were then co-cultured with IFN-γ-licensed MSCs. The exposure to IFN-γ and SARS-CoV-2 NS antigens compromised the viability of Calu-3 cells and induced the expression of the inflammatory mediators ICAM-1, CXCL-10, and IFN-β by these cells. Importantly, despite initially stimulating T-cell activation, IFN-γ-licensed MSCs dramatically reduced IL-6 and IL-10 levels secreted by T-cells exposed to NS antigens and iCM. Moreover, IFN-γ-licensed MSCs were able to significantly inhibit T-cell apoptosis induced by SARS-CoV-2 NS antigens. Taken together, our data show that, in addition to reducing the level of critical cytokines in COVID-19, IFN-γ-licensed MSCs protect T-cells from SARS-CoV-2 antigen-induced apoptosis. Such observations suggest that MSCs may contribute to COVID-19 management by preventing the lymphopenia and immunodeficiency observed in critical cases of the disease.
Epidural analgesia is a popular choice among patients for relief of severe pain associated with labor and delivery. Currently, at the investigators' institution the investigators use a continuous infusion of low dose local anesthetic and narcotic (12 ml/hr of 0.0625% bupivacaine with 2 micrograms/ml fentanyl) after the initial spinal or epidural dose to maintain patient comfort until delivery. This dose of the infusion is chosen because it often provides adequate comfort without interfering with the mobility of the patient and her ability to effectively push during delivery. However, this low-dose epidural infusion strategy often results in recurrence of pain after an initial pain-free period. This recurring pain is known as breakthrough pain and is alleviated by administering small boluses of analgesics via the epidural catheter.

The pain occurring in labor is initially of visceral origin and is mediated by pain fibers originating from the low thoracic and upper lumbar segments of the spinal cord. As labor progresses to the late first phase (also known as transitional stage), pain sensations originating from the distension of the pelvic floor, vagina and perineum adds a somatic component to labor pain. This type of breakthrough pain, mediated by nerve fibers originating from the sacral nerves at dermatomes S2-S4, is often difficult to treat. Patients may experience inadequate analgesia even after boluses of analgesics are administered. Inadequate analgesia is deleterious due to subjective discomfort with its associated neurohumoral and physiological changes, and can be an initiator of the urge to bear down (push). Pushing before complete dilation of the cervix may lead to swelling, cervical injury and premature exhaustion of the mother. Adequate pain control will allow the cervix to fully dilate and motivate the mother to push effectively at the appropriate time. Although requests from patients to alleviate late stage breakthrough pain are common, there are no established data in the literature regarding the most effective strategy for pain management in this stage of labor.

This study is designed to compare the efficacy of two treatments for controlling late first stage breakthrough pain during labor: clonidine-bupivacaine versus fentanyl-bupivacaine. Both strategies are used at Columbia University Medical Center (CUMC) in this clinical situation, and there is no clear evidence whether one is superior.
A method of producing a nanocomposite hydrogel comprises mixing an aqueous composition of water soluble monomer, clay particles and free-radical polymerization initiator, characterized in that i) the polymerization is carried out above the gelation temperature of the resulting polymer and subsequently cooling the polymer to cause gelation, and characterized in that the initiator is selected such that it only dissociates into radicals at a temperature higher than the gelation temperature of the resulting polymer. The gel is formed with clay particles cross-linking the polymer. In preferred embodiments the monomer is N-isopropyl acrylamide. The method provides the advantage that the polymer can be formed and kept in an ungelled state. The hydrogel can be used in the medical field by forming the polymer above the gelation temperature and injecting the ungelled polymer into e.g. a spinal disk, then allowing to cool to form the gel in situ.
FIELD: cosmetics. SUBSTANCE: solvent is a water infusion of shungite of III A group. Mineral is crushed up to size of fractions 1.5-20 mm, mixed with water in ratio 1:1 and aged at room temperature for 2-3 days at periodical mixing. Then infusion is drained and evaporated at atmosphere pressure, in order to reduce it in two times. Then infusion is mixed with solid mineral shungite with fractions size 40-80 mm and aged at room temperature for 4-5 days without mixing. At transportation or prolonged storage of solvent, used as a conserving agent is shungite with fractions size 15-25 mm placed in package in amount of 5-10% from solvent volume. EFFECT: higher efficiency. 3 cl
The application discloses a psoriasis evaluation system based on skin images and skin electric signals. The scoring module calculates a target BSA proportion score according to the tag data set; the electric signal processing module processes the electric signal acquired by the skin electric signal acquisition device to obtain a signal characteristic set. And the condition assessment module classifies the patient condition through the signal feature set and the target BSA proportion score by a K nearest neighbor algorithm to obtain the target condition. The application calculates the target BSA ratio fraction according to the total skin area and the affected area in the skin image of the patient. At the same time, features in the skin electrical signal are extracted, and the condition of the patient is evaluated by the target BSA ratio fraction and the signal features. The severity of psoriasis is evaluated by scores, and objective evaluation of psoriasis is realized. The psoriasis is evaluated more comprehensively and accurately by assisting the skin electric signals.